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Abstract
Mosquitoes (Diptera: Culicidae) are important vectors responsible for transmis-
sion of many diseases and parasites. They are causing millions of deaths every year
and are considered one of the deadliest animals in the world. The most common
arboviruses, such as dengue, chikungunya and Zika, to which the Brazilian popula-
tion is most exposed and that occur through the bites of the Aedes aegypti mosquito,
which is the main aim of this study. These infections caused by these three arbovi-
ruses are widely distributed on the national territory and have severe consequence
to population in some cases. Without effective vaccine and specific treatment, the
maintenance and integration of a continuous entomological and epidemiological
surveillance are important, besides the methods to control and to prevent these
arboviruses in Brazil. This chapter discusses the role of Fiocruz (Oswaldo Cruz
Foundation, the most prominent institution of science and technology in health in
Latin America) for the development of new methodologies to diagnose and control
mosquito-borne diseases through public health policies for the country.
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1. Introduction
The mosquitoes’ ability of disease transmission is studied since the nineteenth
century, although malaria has affected humanity for millennia. Oswaldo Cruz called
it “Amazonian’s elf,” and in the 50th year, a new disease combat method became
important worldwide, the medicated salt of Mario Pinotti. Since this, the efforts of
the Oswaldo Cruz Foundation (Fiocruz) combated and prevented the diseases
transmitted by mosquitoes in Brazil. Among these diseases, we can find malaria,
dengue, Zika and chikungunya. Brazilian territory is an endemic area for their
transmission, considering the tropical climate and the Brazilian population habits.
In the last years, the country was affected by an outbreak caused by chikungunya
virus and by the third arbovirus (Zika virus—ZIKV). These viruses were responsi-
ble for causing a large number of infections [1, 2].
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1.1 Aedes aegypti
The first report about Aedes aegypti is dated from 1925 by Kirkpatrick, in
Egypt [3]. Aedes aegypti is a small dark-colored mosquito with white stripes mark-
ings. Mosquito is considered domesticated animal as much as other animals, such as
the pet dog or cat [3]. These mosquitoes can use natural locations or artificial
containers with waters to lay their eggs, thus tree holes, plant axils and common
household items that can accumulate rainwater, for example, are potential
breeding sites, especially when these locations contain organic material. During
their lifetime, the A. aegypti females are found around the houses and all day long
they are capable of biting humans. Unlike most other mosquitoes, Aedes
mosquitoes are active and bite only during the daytime, with peak activity during
the early morning and in the evening before dusk. They are also capable of biting
other animals, but without transmitting diseases to them. Thus, after feeding on
human blood, they lay her eggs in the still water. These eggs are laid over a period of
several days, and they are resistant to desiccation surviving for long periods of six or
more months, until they have contact with water again, and the larvae are
released [4, 5].
In America regions, A. aegypti is the only epidemiological important species
transmitting the dengue virus. This species is originated from Africa where it was
domesticated and adapted to the environment created by man, becoming
anthropophilic. In the seventeenth century, these mosquitoes started spreading all
over the world, to Mediterranean in the eighteenth century, to tropical Asia in the
nineteenth century and to Pacific Island in the end of the nineteenth century and
beginning of the twentieth century. These adaptive characteristics allowed them to
become abundant in many cities and easily carried to other areas by means of
transport, which increased their vectorial competence, that is, their ability to
become infected by a virus, to replicate it and transmit it. Although A. aegypti
eradication took place in the Mediterranean in the 1950s and between 1950s and
1960s in most countries of the Americas, there was a reinfestation in most of the
areas from which it had been previously eradicated. Nowadays, this vector is con-
sidered a cosmotropical species due to the increasing adaptive capacity of the
A. aegypti [6–10].
In the past, Aedes albopictus has its origin in the Asian jungles, but in conse-
quence of an intense tire trade, by sea, this vector came to the Americas in the
1980s, firstly to the USA and then, in Brazil and in others countries of the Central
and South America, in Africa, Europe but either in some Pacific Island [6].
A. albopictus also lays their eggs in tree holes, but differently of A. aegypti, that
mosquito has their habits outside the household and bites both animals and humans
(anthropophilic and zoophilic diurnal habits). In Asia, A. albopictus is responsible
for the transmission of epidemic outbreaks of classical and hemorrhagic dengue
fever [11].
1.2 Arboviruses: dengue, Zika and chikungunya
Arboviruses (an acronym of ARthropod-BOrne virus) have caused much con-
cern in public health worldwide. Arboviruses have been emerging in different parts
of the world due to genetic changes in the virus, alteration of the host and vector
population dynamics or because of anthropogenic environmental factors. These
viruses’ capacity for adaptation is notable, as well as the likelihood of their emer-
gence and establishment in new geographic areas [12]. Here, we highlight three
important viruses such as dengue virus (DENV), chikungunya virus (CHIKV), and,
lately, Zika virus (ZIKV).
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Dengue is a flaviviruses infection transmitted by mosquitoes of Aedes genus,
mainly A. aegypti and A. albopictus. The dengue virus (DENV) comprises five
distinct serotypes, and this disease is a fast emerging pandemic-prone viral consid-
ered the major public health challenge worldwide [4, 13].
The first epidemic of dengue hemorrhagic fever occurred in Manila, Philippines,
between 1953 and 1954, followed by Bangkok, Thailand and Malaysia in 1958 and
Singapore and Vietnam in 1960. Due to economic growth and consequent increase
of post-World War II urbanization, the epidemic of dengue and hemorrhagic den-
gue spread in the 1970s to other areas of the world, starting in Southeast Asia [10].
In Brazil, since the 1980s, there is an intense virus circulation with epidemic
bursts affecting all the regions of the country [14].
The World Health Organization (WHO) estimates 100 million symptomatic
cases per year and 2.5 billion people are at risk of infection worldwide. There are no
available vaccines and no effective treatment for dengue, which reinforces the need
for strategies to prevent virus transmission by the main vector A. aegypti (Figure 1).
ZIKV is also transmitted by Aedes aegypti, and it was first isolated from a rhesus
macaque (Macaca mulatta) placed as sentinel during a study about yellow fever in
the Zika Forest, Uganda, Africa in 1947 [15]. ZIKV had its first documented out-
break only in 2007 in Micronesia. Since then, the transmission area has spread to
islands in the Pacific Ocean, especially during a great epidemic in Polynesia in
October 2013. In 2015, some cases of humans infected by ZIKV were reported in
Brazil, developing into an outbreak that spread throughout South America, the
Caribbean islands and Central America. Originally adapted to a zoonotic cycle in
Africa, ZIKV evolved into an urban cycle involving a human reservoir and domestic
mosquito vectors [16].
Zika virus was first identified in Uganda in 1947. Before 2007, only sporadic
human cases were reported from countries in Africa and Asia. In 2007, the first
documented Zika virus disease outbreak was reported in the Federated States of
Micronesia. In subsequent years, outbreaks of Zika virus disease were identified in
countries in Southeast Asia and the Western Pacific. Zika virus was identified
for the first time in the Western hemisphere in 2015, when large outbreaks
were reported in Brazil. Since then, the virus spread throughout the Americas
(Figure 2) [17].
Figure 1.
Chronological spread of DENV (adapted from https://www.centralmosquitocontrol.com/resources/disease-inf
ormation/dengue).
3
Aedes aegypti: The Main Enemy of Public Health in Brazil - Challenges…
DOI: http://dx.doi.org/10.5772/intechopen.79780
Zika virus caused large outbreaks in previously unexposed populations, and
from 2013 onward, outbreaks linked with neurological disorders including Guillain-
Barré syndrome and congenital malformations, for reasons that are not yet known.
The future transmission of Zika infection is likely to coincide with the global
distribution of Aedes vectors [19].
A different arbovirus type, an alphavirus, is responsible for causing
chikungunya. Differently than the other two diseases, dengue and Zika,
chikungunya causes prolonged joint pain and persistent immune response.
Chikungunya is a mosquito-borne viral disease first described during an out-
break in southern Tanzania in 1952. It is an RNA virus that belongs to the alphavirus
genus of the family Togaviridae. The name “chikungunya” derives from a word in
the Kimakonde language, meaning “to become contorted” and describes the
stooped appearance of sufferers with joint pain (arthralgia) (Figure 3) [20].
Both A. aegypti and A. albopictus have been implicated in large outbreaks of
chikungunya, whereas A. aegypti is confined within the tropics and sub-tropics,
A. albopictus also occurs in temperate and even cold temperate regions. In recent
Figure 2.
Chronological spread of ZIKV (adapted from Ref. [18]).
Figure 3.
Chronological spread of CHIKV.
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decades, A. albopictus has spread from Asia to become established in areas of Africa,
Europe and the Americas [20].
The first report for A. albopictus in the Americas occurred in Houston (the
United States) in 1985. In Brazil, it was detected for the first time in 1986 in the
states of Rio de Janeiro and Minas Gerais [21, 22]. A. albopictus was essentially a
species wilderness that bred and fed on of the forests and adapted outside houses
and inside houses in the various urban and suburban areas of their distribution,
according to records made by Gomes and Pessoa [23, 24]. This mosquito species is
known as a secondary vector of chikungunya and dengue virus [25].
There is no specific antiviral drug treatment for chikungunya. The treatment is
directed primarily at relieving the symptoms, including the joint pain using antipy-
retics, optimal analgesics and fluids. There is also no commercial chikungunya
vaccine.
2. Clinical diagnosis and treatment for dengue, Zika and chikungunya
fever
The greatest challenge is the differential clinical diagnosis between dengue, Zika
and chikungunya. These three diseases have identical symptomatology and often
the patient may present more than one disease at the same time or even having one
of these diseases without the manifestation of symptoms. The clinical diagnosis can
still occur after some days after the beginning of the infection, but mainly by
laboratorial diagnosis [26–28].
Dengue, Zika and chikungunya infection are diagnosed based on clinical, labo-
ratory and epidemiological criteria. It is an important recognition and differentia-
tion of the clinical symptoms and signs to make the correct diagnosis, start proper
treatment and prevent the associated complications [26–28].
Dengue is an exanthematic febrile disease, which is often accompanied by nau-
sea, aches (especially frontal headache) and pains and responsible for high rates of
morbidity and mortality in countless endemic areas around the world.
In dengue fever, the incubation period lasts for 4–10 days; after that, the disease
has three phases: febrile (lasts 2–7 days with no specific signs and symptoms);
critical (last 24–48 h) and convalescence. The progression to severe dengue infec-
tion (hemorrhagic fever) is variable and difficult to predict [29].
Zika fever and dengue are so similar, characterized by fever, exanthema, head-
ache, conjunctivitis (nonpurulent), myalgia and arthralgia (notably small joints of
hands and feet).
Unlike dengue, Zika presents low morbidity, but it is associated by diseases
such as congenital microcephaly cases and Guillain-Barré syndrome
(a neurological disorder that could lead to paralysis and death), myelitis and
meningoencephalitis [30].
Zika fever is very analogous to dengue, symptom manifests in period of
3–12 days and lasts for 4–7 days. It is estimated that in five infected patients, only
one develop them [31].
Chikungunya fever symptoms are sudden fever accompanied by headache,
polyarthralgia (debilitating) or arthritis and maculopapular rash. The incubation
period lasts for 2–12 days. Symptoms usually disappear in less than 2 weeks, but
arthralgia may last even years. Severe chikungunya can manifest encephalitis,
myocarditis, hepatitis and multiple organ failure that are fatal [32, 33] (Table 1).
Diagnosis of dengue, Zika and chikungunya is primarily clinical. In regions of
epidemic, dengue is primordial, look for warning symptoms and a complete blood
count and transaminases to determinate the phase and severity of the disease. The
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methods for establishing a laboratory diagnosis of these arboviruses are as follows:
(1) detection of the virus for example, cell culture or viral RNA real-time detection;
(2) antibody detection for example, IgM or IgG detection and (3) antigen/antibody
combined detection for example, NS1 and IgM/IgG [27, 28].
These diseases are usually self-limiting with no need for hospitalization except
warning signs are observed, especially severe dengue. There are no specific treat-
ments available. Only symptomatic treatment with nonsalicylic analgesics and
nonsteroid anti-inflammatories drugs are administrated when dengue infection is
discovered. Patients should be advised to drink plenty of fluids to replace fluid lost
from sweating, vomiting and others.
Symptoms* Arboviruses
DENV CHIKV ZIKV
Headache Intense Moderate Moderate
Ganglionar
hypertrophy
Mild Moderate Intense
Cutaneous rash
(exantema)
From the 4th day
(30–50% cases)
Appear from 2nd and 5th
days (50% cases)
Appear from 1st or 2th day
(90–100% cases)
Fever Above 38°C (4–
7 days)
Above 38°C (2–3 days) without febrile and subfebrile 38
(1–2 days of subfebrile)
Itch Mild Mild From moderate to intense
Articulation
swelling
Rare From moderate to intense Mild
Neurological
events
Rare Rare More frequently that DENV and
CHIKV
Conjunctivitis Rare 30% cases 50–90% cases
Joint pain Mild From moderate to intense Moderate
Muscles pain Intense Intense Moderate
Hemorrhage
events
Moderate Mild —
*Adapted from: http://combateaedes.saude.gov.br/pt/sintomas
Table 1.
The main symptoms of dengue, Zika and chikungunya.
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3. Epidemiology
The Brazilian regions with the highest incidence and prevalence of these
diseases (northeast and southeast region) present a favorable climate for the devel-
opment of the Aedes aegypti (Figure 4) and the use of lighter clothes, which cover
smaller areas of the body, favoring their exposure.
The number of suspected or confirmed dengue cases reported to the World
Health Organization (WHO) is showed in Figure 5 as well its distribution in the
world.
In 2015, the incidence of probable cases of dengue fever (number of cases/
100,000 inhabitants), according to Brazilian geographic regions, shows that the
Figure 4.
Brazilian demographic density and latitude at geographic regions.
Figure 5.
Average number of suspected or confirmed dengue cases reported to WHO, 2010–2016.
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Midwest and Southeast regions had the highest incidence: 1451.9 cases/100,000
inhabitants and 1205.7 cases/100,000 inhabitants, respectively. Among the states,
Goiás (2500.6 cases/100,000 inhabitants) and São Paulo (1665.7 cases/100,000
inhabitants) have presented the most incidence numbers [34].
The dengue fever incidence rate was about 733.4 cases/100,000 inhabitants in
all Brazilian States at 2016. During this year, the midwest (1322.0/100,000 inhabi-
tants) and the southeast (1001.2/100,000 inhabitants) regions have presented big-
ger incidence numbers than the other geographic Brazilian regions [35].
In 2017, the midwest region had an incidence of 502.7 cases/100,000 inhabitants
and the northeast region had 151.8 cases/100,000 inhabitants, most notably the
states of Goiás with 947.3 cases/100.00 inhabitants, Ceará with 453.4/100,000
inhabitants and Tocantins with 331.2/100,000 inhabitants [36].
Figure 6 shows the total number cases of dengue in Brazilian regions during
2015–2017, mainly in the Southeast and Northeast regions, due to their characteris-
tic climate aspects.
In 2015, 38,499 suspected chikungunya fever cases were registered in Brazil
(Figure 6) which caused an incidence rate of 18.8 cases/100,000 inhabitants. These
cases were distributed by 704 cities and 17,971 (46.7%) of them and 14 deaths were
confirmed: 05 in Bahia, 02 in Sergipe and 07 in Pernambuco Brazilian states [35].
In 2016, the registered cases number increased significantly to 271,824 and the
incidence rate was 133.0 cases/100,000 inhabitants. These cases were distributed in
2829 cities and 151,318 (55.7%) were confirmed. Once again, the northeast region
had the highest incidence rate. Among the states were: Rio Grande do Norte (723.1
cases/100,000 inhabitants), Ceará (537.7 cases/100,000 inhabitants), Alagoas
(514.8 cases/100,000 inhabitants) and Paraíba (503.0 cases/100,000 inhabitants).
At the same year, 196 deaths caused by Chikungunya fever were confirmed [35].
In 2017, the registered cases number had a slight decrease with 185,737, and the
incidence rate was 90.1 cases/100,000 inhabitants. However, there are 52,285 cases
discarded. During this year, the Northeast region had the highest number of prob-
able chikungunya fever cases (142,131 cases, 76.5%) in relation to the total of the
country. Followed by the Southeast (22,984 cases, 12.4%), North (16,570 cases,
8.9%), Midwest (3679 cases, 2.0%) and South (373 cases, 0.2%) [36].
Figure 6.
Total dengue cases within Brazilian regions at the last 3 years.
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The analysis of the incidence rate of probable cases of chikungunya fever (num-
ber of cases/100,000 inhabitants), according to geographic regions, shows that the
Northeast presents the highest incidence rate: 249.7 cases/100,000 inhabitants.
Among the Brazilian states, we highlight Ceará (1271.0 cases/100,000 inhabitants),
Roraima (795.0 cases/100,000 inhabitants) and Tocantins (207.1 cases/100,000
inhabitants) [36].
The general objective of the Zika surveillance is to describe the epidemiology of
the occurrence of microcephaly related to congenital infections in the national
territory. Thus, from week 45/2015 until week 06/2016, there were 5280 registered
cases of microcephaly occurrence, considering newborns, stillbirths, abortion and
fetuses. Considering the year of notification, 60.1% (3174/5280) were recorded in
2015 and 39.9% (2106/5280) in 2016. [37]. Thus 3174 are confirmed, being 508
confirmed and 203 of these cases distributed in 13 Brazilian states, mainly in
Northeast region (93.6%). Southeast region presented only five microcephaly noti-
fied cases. At least 27 of the confirmed cases evolved to death after birth or during
pregnancy. At the end of 2016, the number of reported cases of the microcephaly
increased to 10,867. Of these, 3183 (29.3%) remain under investigation and 7684
(70.7%) cases were investigated and classified, being 2366 confirmed, 49 probable
and 5269 discarded. According to the geographical distribution, confirmed cases of
the 10,867 reported are distributed in 751 Brazilian cities of the 27 Brazilian states,
mainly in Northeast region (75.3%). The southeast region showed a large increase in
the number of confirmed cases of microcephaly: 74 cases [38].
Due to this epidemiological situation of Zika viruses and its consequences, this
disease is considered an Emergency in Public Health of National Importance
(ESPIN). From week 45/2015 and until week 52/2017,there were 15,298 cases noti-
fied of suspected changes in growth and possibly related to infection with the Zika
virus and other infectious etiologies, of which 2869 (18.8%) remained research until
2017, December. Of the total cases, 3071 (20.1%) were confirmed, 339 (2.2%) were
classified as likely to be related to infection during pregnancy and 230 (1.5%) as
inconclusive. The majority of cases reported is concentrated in the Northeast region
of the country (60.6%), followed by the Southeast (23.9%) and Midwest region
(7.3%). The five Brazilian states with the greatest number of reported cases are
Pernambuco (16.8%), Bahia (16.3%), São Paulo (9.0%), Paraíba (7.3%) and Rio de
Janeiro (7.3%) [39].
Figure 7.
Cases of dengue, chikungunya and Zika fever in Brazil during 2015, 2016 and 2017.
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Nowadays, the 542 microcephaly cases confirmed in Brazil between weeks 1 and
52/2017, 204 (37.6%) received care in childcare. The confirmed children were
concentrated in the Southeast (183 cases). Attending in precocious stimulation was
performed in 100 of the 542 (18.5%) of confirmed cases, while care in specialized
care occurred in 184 of the 542 (33.9%) confirmed cases [39].
Figure 7 shows the behavior of these three diseases in relation to the number of
registered cases for the period 2015–2017.
These epidemiology data have demonstrated the incidence rates of the three
arboviruses among 2015–2017. In 2016, the incidence of dengue cases has slightly
decreased. In 2017, although the numbers of dengue have decreased, the cases of
Zika and chikungunya increased, consequently the occurrence of accompany Zika
diseases increases during the same period, mainly the microcephaly cases [35–39].
4. Control and prevention
For residents in areas populated by the Aedes aegypti species, the most important
preventative measure they can take is to remove standing water wherever possible
to eliminate breeding sites. This species can breed in as little as one tablespoon of
water, so every effort should be made to eliminate standing water in buckets, old
tires, gutters, birdbaths, flower pots and more. Additionally, residents should pro-
tect themselves indoors with the use of air conditioning and properly maintained
window screens and outdoors with the use of mosquito repellents containing DEET
(N,N-diethyl-meta-toluamide) and loose fitting clothing [40]. At present, the con-
trol of dengue disease is mainly hampered by the absence of antivirals or a vaccine,
which results in an estimated half worldwide population at risk of infection.
Currently, antiviral treatment against dengue is available, and the development
of an effective anti-dengue vaccine would represent a cornerstone in public health.
An important aspect of dengue is that an effective immunity can be potentially
impaired during heterologous infections (refers to the immunity that can develop to
one pathogen after a host has had exposure to nonidentical pathogens), which may
lead to severe manifestations of dengue and represents a great burden in the devel-
opment of a vaccine against this pathogen.
Due to the absence of an effective vaccine for these arboviruses, the control is
still accomplished through the prevention and elimination of potential mosquito-
breeding habitats. Thus, the use of chemical insecticides is yet the main vector
control component. Alternative products, with potential to be used in the control of
A. aegypti, including the biolarvicide Bti (Bacillus thuringiensis var. israelensis) and
some insect growth regulators are also being used recently [41].
4.1 Vaccination
It is widely recognized that passive vaccination is the most appropriate preven-
tive and therapeutic option but till now no vaccine is available for Zika and
chikungunya although some initiative to the development of a vaccine have been
tested. Several vaccine approaches have been used such as inactivated viral vac-
cines, live-attenuated viruses, recombinant subunit vaccines, DNA vaccination and
others. In Brazil, a live-attenuated viruses vaccine developed by Sanofi Pasteur
laboratory has been available since 2016. It is sold in private clinics and is part of
vaccination pilot public programs in Paraná state. The product requires three appli-
cations with an interval of 6 months between them. In the early studies, the efficacy
in the population above 9 years old is approximately 66% against the four serotypes
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of dengue virus. In addition, it reduces severe cases—those that lead to death, such
as hemorrhagic dengue—by 93% and hospitalization rates by 80%.
Pending vaccine development, the measures recommended to prevent against
mosquito bites and vector control consist of individual protection or action. Mos-
quito control is the best available method for preventing arboviruses infection.
Breeding sites must be removed, destroyed, cleaned and treated with insecticides.
4.2 Repellents and larvicides
About the intervention against mosquitoes, mainly Aedes aegypti, the use of new
repellents and insecticides agents are investigated. Due to the development of
resistance, biological magnification of toxic substances through the food chain, and
others adverse effects on the environment and human health caused by the syn-
thetic insecticides, eco-friendly agents control of mosquitoes vectors have a great
importance to avoid dengue, Zika and chikungunya and others diseases transmitted
by A. aegypti. By this way, so many natural products as plant extracts and essential
oils have been evaluated against larval and pupal stages of A. aegypti as
nanoparticles containing plant extracts and the essential oils from Zingiber officinale,
Curcuma longa, Ocimum basilicum, andMentha piperita which variety of types and
levels of their actives constituents could be responsible for their potential to combat
mosquitoes and have been shown to be promising and low-cost mosquitoes control
strategies [42–45].
Other intervention, could be done such as using repellents with DEET, wear
cloth which minimizes skin exposure to the day-biting vectors, stay in places with
air conditioning, use domestic insecticides in aerosol form or in vaporizers within
the home.
The conventional methods such as insecticides and larval biological used until
now revealed that control have proven ineffective at halting disease spreading
[46, 47]. A successful system controlling a broad spectrum of approaches should be
mutually compatible and encompass including the development of novel insecti-
cides, transgenic disease-resistant mosquitoes, the release of sterile insects to sup-
press vector populations and equipment for preventing mosquito bites is to be
developed [48].
In Brazil, some new approaches to control mosquito have shown considerable
promise in latest years are the biolarvicide Bti, the genetic control of A. aegypti
mosquitoes and the development of mosquitoes that are resistant to arbovirus
infection [47].
Brazil was among the pioneers in adopting Bti to control mosquitoes and black
flies. Developed by research groups in Brazilian institutions, this bacterial larvicide
is highly toxic at very low doses to target organisms (mosquito and black flies
larvae) and safe to other nontarget organisms. Larvicidal activity is due to large
amounts of crystal proteins produced during sporulation and transformed into
toxins under specific conditions after ingestion by larvae. The structure of the pro-
teins made by the bacterium strain and the presence of proteolytic enzymes and
receptor in the host larvae midgut determined the selectivity observed. Brazilian
product showed some advantages such as reduction in the number of applications,
formulation with high storage stability, no environmental impact and high persis-
tence in the environment and especially efficient in tropical climates [49].
4.3 Biological control of mosquitoes
One way to control mosquitoes is the genetic control strategy known as release
of insects carrying dominant lethal genes (RIDL) which is an advancement of the
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environmentally benign sterile insect technique (SIT). The RIDL involves the
insertion of a lethal gene into male mosquitoes that prevents them from being able
to reproduce successfully. The insects are considered sterile because the vast
majority dies before maturing. These genetically modified males will seek out
females to mate with and the ensuing progeny will contain the lethal gene [50–52].
If an appropriate number of mosquitoes are released, the females will be more likely
to find a modified male, and a substantial drop in population can be achieved in a
remarkably short period. To control populations with this technique as “zones” of
release should be established to ensure sufficient area coverage. The preliminary
results in Brazil showed that successful approach achieved a 95% reduction in local
mosquito populations [53].
Another alternative approach to A. aegypti control is the use of mosquitoes with
theWolbachia pipientis an endosymbiotic bacterium to prevent arboviruses repli-
cating within the mosquito. The bacteria can hinder the fertility of their hosts and
influence the sex of offspring. Besides, it can block viruses from reproducing in
infected fruit flies and mosquitoes [50, 52, 53]. Mosquito control is an effective
measure to prevent a dengue outbreak [54].
FIOCRUZ’s initiative to produce, create and release adult mosquitoes infected by
bacterium ofWolbachia genus in several districts of the city of Rio de Janeiro has
been shown to be very effective in controlling the diseases transmitted by Aedes
aegypti.
Other mosquitoes genetically modified (Moscamed™, created in 2005) are pro-
duced in large scale and released in different cities of Bahia states, reducing the
mosquito population in 95% during 6 months. These strategies are being expanded
throughout the Brazilian territory to combat Aedes aegypti [55, 56].
4.4 Control of mosquitoes by the Brazilian government
• Monthly/bimonthly inspection of households/population orientation by
health agents;
• Application of larvicides in the houses (more than 300,000 nonmilitary health
agents +220,000 soldiers fighting against potential mosquitoes breeding sites);
• Smoke dispersion containing neurotoxic agent to adult mosquitoes at
epidemic locals;
• Biological control through the use of a bacterium naturally found in the
environment, Wolbachia, which when present in Aedes, is able to prevent the
transmission of the disease by the mosquitoes, and this characteristic is passed
through on to their larvae.
5. The role of Fiocruz
In Brazil, dengue has a seasonal pattern, with a higher incidence of cases in the
first 5 months of the year, a warmer and wetter period, typical of tropical climates.
In the second half of the twentieth century, from 1986, dengue became epidemio-
logically important, when the epidemic broke out in the State of Rio de Janeiro and
the circulation of serotype 1, which soon reached the Northeast Region. Thus,
dengue became endemic in Brazil, interspersed with epidemics, usually
associated with the introduction of new serotypes, in areas previously indene
[14, 55–58].
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The Oswaldo Cruz Foundation (Fiocruz), under the Ministry of Health have a
mission to produce, disseminate and share knowledge and technologies aimed at the
strengthening and consolidation of the Unified Health System (SUS) and contribute
to the promotion of health and quality of life of the population [59].
Since 2003, in order to promote dengue control actions, Fiocruz has established
the Fiocruz Dengue Network, through the allocation of resources to the Program
for Development and Technological Innovation in Public Health in the field
of research.
With the epidemiological cycles of the disease continuing, repeating itself and
spreading throughout the country, more than 30,000 cases of dengue fever were
reported in the city of Rio de Janeiro in 2008. Due to this epidemic, Fiocruz was
called to assist the state and municipality in actions to combat the disease.
Thus, from 2009, Fiocruz redirected an integral focus to the issue with coverage
in these three areas, without excluding the research. The Network Health Care of
Integrated Actions for Health Care in Dengue Control originated from 2015
onwards and began to include in its scope the issues related to two emerging viruses
in Brazil: chikungunya and Zika.
Aiming to reduce or even block the transmission of Zika, dengue and
chikungunya Fiocruz has set up a factory for the large-scale release of Aedes aegypti
Wolbachia bacterium in Rio de Janeiro. The plant has the capacity to produce
10 million eggs of the mosquito per week.
The initiative, officially called “Eliminating Dengue: Brazil Challenge,” began in
2016 as a pilot project focused on the city of Niterói and the Tubiacanga neighbor-
hood of Rio. According to the project’s schedule, it will expand to North and South
zones of Rio de Janeiro. The release of mosquitoes will be finalized by the end of
2018, at which time the project’s coverage will have increased to a total area occu-
pied by approximately 2.5 million people.
The Oswaldo Cruz Foundation (Fiocruz) developed a new test that will help
drive public policies to fight the health emergency caused by the three infection
diseases. The kit uses molecular diagnostics to detect and differentiate simultaneous
RNA of the three viruses through real-time PCR technology, and the result is
released on the same day. The kit can be used for laboratory diagnosis of all three
viruses, two of them or each separately. The test allows diagnosis in the critical
phase of the disease, at the beginning of clinical symptoms and an accurate labora-
tory diagnosis is essential. The opportunity or earlier diagnosis can also aid for
epidemiological surveillance and prevention of new cases.
Fiocruz maintains investment in research, development and innovation because
this is the only way to seek and find answers to the challenges due to triple Zika-
dengue-chikungunya epidemic. Therefore, the goal is to search for cooperation with
other institutions in Brazil and internationally to build projects that could offer new
possibilities to generate knowledge and developing technologies.
6. Conclusion
Aedes aegypti is still a worldwide threat, since more than half of the world’s
population live in areas where these mosquitoes species are present. However,
many efforts have been undertaken to combat and to control these mosquitoes and
the diseases transmitted by them, such as vaccination, repellents and larvicides and
the biological control of mosquitoes. Brazil has been continuously developing public
policies to health education, alerting the population on the risks which can be
avoided, with the purpose of decreasing the dengue, Zika and chikungunya dis-
eases. The Brazilian government plays a role in continuing investment in research,
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development and innovation to find new ways with national and international
cooperation to combat Aedes aegypti.
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